Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients, AIDS, vol.29, issue.16, pp.2099-108, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01288887
Class of antiretroviral drugs and the risk of myocardial infarction, N Engl J Med, vol.356, issue.17, pp.1723-1758, 2007. ,
Cardiovascular Disease, Statins, and HIV. The Journal of infectious diseases, vol.214, p.5021243, 2016. ,
HIV and coronary heart disease: time for a better understanding, J Am Coll Cardiol, vol.61, issue.5, pp.511-534, 2013. ,
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a casecontrol study nested within the French Hospital Database on HIV ANRS cohort CO4, Arch Intern Med, vol.170, issue.14, pp.1228-1266, 2010. ,
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study, Lancet HIV, 2018. ,
, Epub 2018/05/08, vol.5, pp.30043-30045
Bilirubin in coronary artery disease: Cytotoxic or protective?, World J Gastrointest Pharmacol Ther, vol.7, issue.4, p.5095566, 2016. ,
Limiting cardiovascular events associated with HIV and antiretroviral therapy, AIDS, vol.31, issue.18, pp.2551-2554, 2017. ,
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study, The Journal of antimicrobial chemotherapy, vol.74, issue.9, pp.2742-51, 2019. ,
48-week changes in biomarkers in subjects with high cardiovascular risk boosted switching from ritonavir-protease inhibitors to dolutegravir: the NEAT022 study, Journal of the International AIDS Society, vol.21, issue.S8, p.25187, 2018. ,
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age >/ = 50 Years: Final 96-Week Results of the NEAT022 Study, vol.68, pp.597-606, 2019. ,
Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials, Curr Opin HIV AIDS, vol.13, issue.2, pp.102-113, 2018. ,
, CARDIOVASCU-LAR DISEASE RISK ASSOCIATED WITH INTEGRASE INHIBITORS. CROI, 2019.
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV, N Engl J Med, vol.381, issue.9, pp.803-818, 2019. ,
Are new antiretroviral treatments increasing the risks of clinical obesity?, J Virus Erad, vol.5, issue.1, pp.41-44, 2019. ,
, GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS. CROI, 2019.
,
, RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR-BASED ART, 2019.
Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, Epub 2019/05/18, 2019. ,
Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil ,
URL : https://hal.archives-ouvertes.fr/hal-01999822
Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s, Open Forum Infect Dis, vol.3, issue.3, p.5047417, 2016. ,
, DOLUTEGRAVIR AND INSULIN RESISTANCE. CROI, 2019.
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study, Open Forum Infect Dis, vol.6, issue.4, p.6446135, 2019. ,
Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients, Scientific reports, vol.6, p.4926207, 2016. ,
Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence, Antiviral therapy, vol.22, issue.8, pp.645-57, 2017. ,
CXC and CC chemokine receptors on coronary and brain endothelia, Mol Med, vol.5, issue.12, pp.795-805, 1999. ,
, , p.2230493
The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro, Cardiovascular research, vol.101, issue.3, p.3928001, 2014. ,
Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin, Antiviral therapy, vol.19, issue.8, pp.773-82, 2014. ,
The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice, Am J Physiol Heart Circ Physiol, vol.307, issue.12, p.4269699, 2014. ,
SRT1720, a SIRT1 specific activator, protected H2O2-induced senescent endothelium, Am J Transl Res, vol.8, issue.7, p.4969425, 2016. ,
Reduced thrombosis in Klkb1-/-mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor, Blood, vol.125, issue.4, p.4304115, 2015. ,
Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP/PKA signaling inhibition of ERK pathway, Eur J Pharmacol, vol.688, issue.1-3, pp.68-75, 2012. ,
Endothelial PPARgamma provides vascular protection from IL-1beta-induced oxidative stress, Am J Physiol Heart Circ Physiol, vol.310, issue.1, p.4796462, 2016. ,
Ten-year improvement of insulin resistance and growth with recombinant human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in leprechaunism, Diabetes Metab, vol.41, issue.4, pp.331-338, 2015. ,
Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I. The Journal of clinical endocrinology and metabolism, vol.84, pp.3197-206, 1999. ,
USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity, Hepatology, vol.66, issue.6, pp.1866-84, 2017. ,
USP18 inhibits NF-kappaB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex, J Exp Med, vol.210, issue.8, pp.1575-90, 2013. ,
, , p.3727316
USP18 negatively regulates NF-kappaB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms, Scientific reports, vol.5, 2015. ,
,
The impact of insulin resistance on the kidney and vasculature, Nat Rev Nephrol, vol.12, issue.12, pp.721-758, 2016. ,
Exercise ameliorates insulin resistance via regulating TGFbetaactivated kinase 1 (TAK1)-mediated insulin signaling in liver of high-fat diet-induced obese rats, J Cell Physiol, vol.234, issue.5, pp.7467-74, 2019. ,
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir, AIDS, vol.26, issue.18, pp.2315-2341, 2012. ,
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically, AIDS, vol.20, issue.14, pp.1813-1834, 2006. ,
Switch to dolutegravir (DTG) from a boosted protease inhibitor (PI/r) associated with significant weight gain over 48 weeks in NEAT-022, a randomised 96-week trila, HIV Drug Therapy, 2018. ,
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, vol.62, p.4787610, 2016. ,
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial, Lancet HIV, vol.6, issue.6, pp.364-72, 2019. ,
The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection, Current HIV/ AIDS reports, vol.14, issue.6, p.5694708, 2017. ,
Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy, PloS one, vol.13, issue.5, p.5944924, 2018. ,
Cellular and molecular biology of aging endothelial cells, J Mol Cell Cardiol, vol.89, p.4522407, 2015. ,
FOXOs and sirtuins in vascular growth, maintenance, and aging, Circ Res, vol.110, issue.9, pp.1238-51, 2012. ,
Sirtuin function in aging heart and vessels, J Mol Cell Cardiol, vol.83, pp.55-61, 2015. ,
USP18-a multifunctional component in the interferon response, Biosci Rep, vol.38, issue.6, 2018. ,
, , p.6240716